James M Markert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1176619/publications.pdf

Version: 2024-02-01

70	3,963	147801	123424
papers	citations	31 h-index	61 g-index

71	71	71	3373
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting. Molecular Therapy, 2004, 10, 958-966.	8.2	401
2	Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM. Molecular Therapy, 2009, 17, 199-207.	8.2	346
3	Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with Attenuated Herpes Simplex Mutants that Retain Susceptibility to Acyclovir. Neurosurgery, 1993, 32, 597-603.	1.1	244
4	A Phase I Trial of Intratumoral Administration of Reovirus in Patients With Histologically Confirmed Recurrent Malignant Gliomas. Molecular Therapy, 2008, 16, 627-632.	8.2	243
5	A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses. Molecular Therapy, 2014, 22, 1048-1055.	8.2	233
6	Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas. New England Journal of Medicine, 2021, 384, 1613-1622.	27.0	173
7	Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of Mitochondrial Electron Transport Chain. Journal of Biological Chemistry, 2010, 285, 39759-39767.	3.4	158
8	Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults. Molecular Therapy, 2014, 22, 1056-1062.	8.2	119
9	Oncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas. Journal of Neuro-Oncology, 2003, 65, 203-226.	2.9	113
10	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Human Gene Therapy Clinical Development, 2016, 27, 69-78.	3.1	113
11	Oncolytic Virotherapy for the Treatment of Malignant Glioma. Neurotherapeutics, 2017, 14, 333-344.	4.4	108
12	Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro-Oncology, 2005, 7, 213-224.	1.2	107
13	Initial treatment of melanoma brain metastases using gamma knife radiosurgery. Cancer, 2004, 101, 825-833.	4.1	86
14	Oncolytic Viral Therapy of Malignant Glioma. Neurotherapeutics, 2009, 6, 558-569.	4.4	79
15	Predictors of Distant Brain Recurrence for Patients With Newly Diagnosed Brain Metastases Treated With Stereotactic Radiosurgery Alone. International Journal of Radiation Oncology Biology Physics, 2008, 70, 181-186.	0.8	77
16	Genetically engineered HSV in the treatment of glioma: a review. , 2000, 10, 17-30.		74
17	Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. Journal of Neuro-Oncology, 2009, 95, 199-209.	2.9	74
18	Preclinical Evaluation of a Genetically Engineered Herpes Simplex Virus Expressing Interleukin-12. Journal of Virology, 2012, 86, 5304-5313.	3.4	68

#	Article	IF	Citations
19	Evaluation of the Safety and Biodistribution of M032, an Attenuated Herpes Simplex Virus Type 1 Expressing hIL-12, After Intracerebral Administration toAotusNonhuman Primates. Human Gene Therapy Clinical Development, 2014, 25, 16-27.	3.1	59
20	Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Therapy, 2005, 12, 359-368.	4.6	57
21	Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Scientific Reports, 2018, 8, 13930.	3.3	56
22	Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. Neuro-Oncology, 2016, 18, 227-235.	1.2	53
23	Histone Deacetylase Inhibitors Improve the Replication of Oncolytic Herpes Simplex Virus in Breast Cancer Cells. PLoS ONE, 2014, 9, e92919.	2.5	48
24	Preclinical evaluation of ex vivo expanded/activated Î³Î´ T cells for immunotherapy of glioblastoma multiforme. Journal of Neuro-Oncology, 2011, 101, 179-188.	2.9	47
25	Herpes Simplex Virus Oncolytic Therapy for Pediatric Malignancies. Molecular Therapy, 2009, 17, 1125-1135.	8.2	45
26	Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors. Human Gene Therapy Clinical Development, 2017, 28, 7-16.	3.1	45
27	Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance. Oncogene, 2019, 38, 6159-6171.	5.9	45
28	Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy. Frontiers in Oncology, 2017, 7, 136.	2.8	40
29	Prognostic Relevance of Cytochrome c Oxidase in Primary Glioblastoma Multiforme. PLoS ONE, 2013, 8, e61035.	2.5	39
30	To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses. Viruses, 2016, 8, 43.	3.3	36
31	Hypoxia Moderates Î³134.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures. Translational Oncology, 2012, 5, 200-207.	3.7	35
32	STAT1 and NF-ÎºB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells. Molecular Cancer Research, 2016, 14, 482-492.	3.4	34
33	Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates. Molecular Therapy - Oncolytics, 2017, 5, 1-10.	4.4	33
34	Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine, 2006, 24, 1644-1652.	3.8	31
35	Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology. Theranostics, 2019, 9, 5085-5104.	10.0	29
36	Preclinical Evaluation of Oncolytic Î”Î³₁34.5 Herpes Simplex Virus Expressing Interleukin-12 for Therapy of Breast Cancer Brain Metastases. International Journal of Breast Cancer, 2012, 2012, 1-12.	1.2	26

#	Article	IF	Citations
37	Use of the Extreme Lateral Approach in the Surgical Treatment of an Intradural Ventral Cervical Spinal Cord Vascular Malformation: Technical Case Report. Neurosurgery, 1996, 38, 412-415.	1.1	25
38	Chimeric HCMV/HSV-1 and Î”Î³134.5 oncolytic herpes simplex virus elicit immune mediated antiglioma effect and antitumor memory. Translational Oncology, 2018, 11, 86-93.	3.7	24
39	Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors. Human Gene Therapy, 2020, 31, 1132-1139.	2.7	24
40	Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma. PLoS ONE, 2013, 8, e77753.	2.5	21
41	Serial Passage through Human Glioma Xenografts Selects for a Î”Î³ 1 34.5 Herpes Simplex Virus Type 1 Mutant That Exhibits Decreased Neurotoxicity and Prolongs Survival of Mice with Experimental Brain Tumors. Journal of Virology, 2006, 80, 7308-7315.	3.4	20
42	Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas. Neurosurgical Focus, 2021, 50, E5.	2.3	20
43	Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children. Molecular Therapy - Oncolytics, 2015, 2, 15015.	4.4	19
44	A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition. OncoImmunology, 2019, 8, e1678921.	4.6	18
45	Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of Herpes Simplex Virus -1 G207 in Pediatric Malignant Supratentorial Brain Tumors. World Neurosurgery, 2019, 122, e1592-e1598.	1.3	17
46	Stereotactic radiosurgical treatment of brain metastasis of primary tumors that rarely metastasize to the central nervous system. Journal of Neuro-Oncology, 2012, 109, 513-519.	2.9	16
47	Oncolytic HSV-1 for the treatment of brain tumours. Herpes: the Journal of the IHMF, 2006, 13, 66-71.	0.3	15
48	Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma. Journal of Immunology Research, 2016, 2016, 1-10.	2.2	14
49	Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas. Neurosurgery Clinics of North America, 2021, 32, 265-281.	1.7	14
50	Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience. Neuro-Oncology Practice, 2014, 1, 172-177.	1.6	13
51	Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002. Molecular Therapy - Oncolytics, 2017, 7, 27-36.	4.4	13
52	Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study. PLoS Medicine, 2019, 16, e1002810.	8.4	13
53	Positron emission tomography imaging with 89Zr-labeled anti-CD8 cys-diabody reveals CD8+ cell infiltration during oncolytic virus therapy in a glioma murine model. Scientific Reports, 2021, 11, 15384.	3.3	13
54	Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study. Clinical Cancer Research, 2022, 28, 498-506.	7.0	12

#	Article	IF	Citations
55	Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy. Frontiers in Oncology, 2013, 3, 28.	2.8	11
56	Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children. Molecular Therapy - Oncolytics, 2015, 2, 15016.	4.4	11
57	Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis. Journal of Neuro-Oncology, 2019, 141, 289-301.	2.9	11
58	Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Pediatric Solid Tumors. PLoS ONE, 2014, 9, e86843.	2.5	10
59	Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma. Translational Oncology, 2016, 9, 419-430.	3.7	8
60	Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy. Cancers, 2022, 14, 762.	3.7	7
61	The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas. Frontiers in Surgery, 2020, 7, 59.	1.4	5
62	A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastases. Advances in Radiation Oncology, 2016, 1, 83-88.	1.2	4
63	Evaluation of the Safety and Biodistribution of M032, an Attenuated HSV-1 Virus Expressing hIL-12, After Intracerebral Administration to Aotus Non-Human Primates. Human Gene Therapy Clinical Development, 0, , 150127063140004.	3.1	3
64	Combination strategies enhance oncolytic virotherapy. Oncotarget, 2017, 8, 34020-34021.	1.8	3
65	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Human Gene Therapy Clinical Development, 0, , .	3.1	2
66	Spontaneous cerebellar hemorrhage in a patient taking apixaban. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2015, 2, 54-56.	0.3	1
67	Biologic warfare for a good cause: HSV-1 anti-tumor therapy. Clinical Neurosurgery, 2004, 51, 73-80.	0.2	1
68	Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neuro-Oncology Advances, 2022, 4, vdab186.	0.7	1
69	Herpesviruses as therapeutic agents. , 0, , 1341-1352.		0
70	Commentary: Developing a Professionalism and Harassment Policy for Organized Neurosurgery. Neurosurgery, 2021, 89, E60-E60.	1.1	0